<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62146">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02296892</url>
  </required_header>
  <id_info>
    <org_study_id>CNS7056-008</org_study_id>
    <nct_id>NCT02296892</nct_id>
  </id_info>
  <brief_title>A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy</brief_title>
  <official_title>A Phase III Study Evaluating the Efficacy and Safety of Remimazolam (CNS 7056) Compared to Placebo and Midazolam in Patients Undergoing Bronchoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paion UK Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Paion UK Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, double-blind, randomized, placebo and active controlled, multi-center,
      parallel group study comparing remimazolam to placebo, with an additional open label arm for
      midazolam, in patients undergoing a bronchoscopy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success of Procedure</measure>
    <time_frame>From first dose of study drug to removal of bronchoscope</time_frame>
    <description>Measured by completion of bronchoscopy, no requirement for an alternative sedative and no requirement for more than 5 top-ups of study medication within any 15 minute period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to start of procedure</measure>
    <time_frame>From first dose of study drug until insertion of the bronchoscope, on Day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak sedation</measure>
    <time_frame>From first dose of study drug until the lowest level of sedation, which has occurred during the bronchoscopy procedure, on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ready for discharge</measure>
    <time_frame>From the end of the bronchoscopy and after the last dose of study drug, until discharge, expected to be the same day.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to fully alert</measure>
    <time_frame>From the last dose of study drug, until the patient has recovered to fully alert. Expected to be the same day.</time_frame>
    <description>Sedation will be measured using the MOAA/S scale every 30 seconds for the first 3 minutes and every minute thereafter until fully alert. Fully alert is defined as 3 consecutive MOAA/S scores of 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>From first dose of study drug until Day 4, or resolution of any ongoing adverse events.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Bronchoscopy</condition>
  <arm_group>
    <arm_group_label>Remimazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remimazolam iv 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo iv for sedation induction and maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam iv 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance. *1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam</intervention_name>
    <description>For induction and maintenance of sedation</description>
    <arm_group_label>Remimazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For induction and maintenance of sedation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>For induction and maintenance of sedation</description>
    <arm_group_label>Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled to undergo a diagnostic or therapeutic fiberoptic bronchoscopy in
             the bronchoscopy suite (e.g. lavage, biopsies, brushings, foreign body extraction)

        Exclusion Criteria:

          -  Bronchoscopy outside the bronchoscopy suite (e.g. Intensive Care Unit)

          -  SpO2 &lt; 90% in ambient air, or patients on chronic continuous O2 support or on
             mechanical ventilation

          -  Forced expiratory volume (FEV1) &lt; 1L

          -  Tracheal stenosis

          -  Planned laser bronchoscopy, rigid scope bronchoscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Johns Hopkins Center for Interventional and Pulmonary Care</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yarmus</last_name>
      <phone>410-955-5288</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerard Silvestri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates of Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Hey</last_name>
      <phone>804-323-7002</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 4, 2016</lastchanged_date>
  <firstreceived_date>November 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
